MY172643A - Diagnosis of entamoeba histolytica - Google Patents

Diagnosis of entamoeba histolytica

Info

Publication number
MY172643A
MY172643A MYPI2011003202A MYPI2011003202A MY172643A MY 172643 A MY172643 A MY 172643A MY PI2011003202 A MYPI2011003202 A MY PI2011003202A MY PI2011003202 A MYPI2011003202 A MY PI2011003202A MY 172643 A MY172643 A MY 172643A
Authority
MY
Malaysia
Prior art keywords
histolytica
diagnosis
entamoeba histolytica
subject
mutant
Prior art date
Application number
MYPI2011003202A
Inventor
Binti Noordin Rahmah
Huat Lim Boon
Mohamed Zeehaida
Othman Nurulhasanah
Kin Wong Weng
Ning Tan Zi
Original Assignee
Univ Sains Malaysia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Sains Malaysia filed Critical Univ Sains Malaysia
Priority to MYPI2011003202A priority Critical patent/MY172643A/en
Priority to IN626CHN2014 priority patent/IN2014CN00626A/en
Priority to MX2014000007A priority patent/MX358619B/en
Priority to BR112014000135A priority patent/BR112014000135A2/en
Priority to PCT/MY2011/000172 priority patent/WO2013006024A1/en
Priority to CO14008609A priority patent/CO6940378A2/en
Priority to ZA2014/00469A priority patent/ZA201400469B/en
Publication of MY172643A publication Critical patent/MY172643A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

An in vitro method of diagnosing and/or treating at least one subject as having or as being at risk of having Entamoeba histolytica (E. histolytica) infection, the method comprising detecting the presence of at least one E. histolytica protein, fragment, variant or mutant thereof in a serum sample from the subject, wherein the presence of the protein, fragment, variant or mutant thereof is indicative of the subject having or as being at risk of having E. histolytica infection.
MYPI2011003202A 2011-07-07 2011-07-07 Diagnosis of entamoeba histolytica MY172643A (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
MYPI2011003202A MY172643A (en) 2011-07-07 2011-07-07 Diagnosis of entamoeba histolytica
IN626CHN2014 IN2014CN00626A (en) 2011-07-07 2011-07-20
MX2014000007A MX358619B (en) 2011-07-07 2011-07-20 Diagnosis of entamoeba histolytica.
BR112014000135A BR112014000135A2 (en) 2011-07-07 2011-07-20 diagnosis of entamoeba histolytica
PCT/MY2011/000172 WO2013006024A1 (en) 2011-07-07 2011-07-20 Diagnosis of entamoeba histolytica
CO14008609A CO6940378A2 (en) 2011-07-07 2014-01-17 Diagnosis of entamoeba histolylica
ZA2014/00469A ZA201400469B (en) 2011-07-07 2014-01-21 Diagnosis of entamoeba histolytica

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MYPI2011003202A MY172643A (en) 2011-07-07 2011-07-07 Diagnosis of entamoeba histolytica

Publications (1)

Publication Number Publication Date
MY172643A true MY172643A (en) 2019-12-07

Family

ID=47437247

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2011003202A MY172643A (en) 2011-07-07 2011-07-07 Diagnosis of entamoeba histolytica

Country Status (7)

Country Link
BR (1) BR112014000135A2 (en)
CO (1) CO6940378A2 (en)
IN (1) IN2014CN00626A (en)
MX (1) MX358619B (en)
MY (1) MY172643A (en)
WO (1) WO2013006024A1 (en)
ZA (1) ZA201400469B (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130417A (en) * 1990-04-30 1992-07-14 Washington University Entamoeba histolytical immunogenic protein and cdna clone
MX9206019A (en) * 1992-10-20 1994-04-29 Univ Autonoma De Nuevo Leon PROCEDURE FOR THE PRESERVATION OF ANTIGENIC MOLECULES WITHOUT THE USE OF ENZYMATIC INHIBITORS.

Also Published As

Publication number Publication date
WO2013006024A1 (en) 2013-01-10
BR112014000135A2 (en) 2018-06-19
CO6940378A2 (en) 2014-05-09
ZA201400469B (en) 2015-08-26
MX2014000007A (en) 2015-02-12
IN2014CN00626A (en) 2015-04-03
MX358619B (en) 2018-08-28

Similar Documents

Publication Publication Date Title
BR112014031365A2 (en) methods of detecting disease or conditions
EP2576833A4 (en) Methods and apparatus for point-of-care detection of nucleic acid in a sample
EP2829881A3 (en) Diagnostic for colorectal cancer
TN2013000358A1 (en) Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects
WO2012054589A3 (en) Conduit-containing devices and methods for analyte processing and detection
WO2010056337A3 (en) Methods and systems of using exosomes for determining phenotypes
EP4234583A3 (en) Evaluation and treatment of bradykinin-mediated disorders
MX2014003422A (en) Method for monitoring, diagnosis and/or prognosis of acute kidney injury in early stage.
NZ593514A (en) p-mTOR and p-AKT as Ratio Based Biomarkers for the Prognosis and/or Diagnosis of Cancer
EP2569635A4 (en) Methods for diagnosing and treating encephalitis or epilepsy
EP2566983A4 (en) Serial analysis of biomarkers for disease diagnosis
PH12015502849B1 (en) Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
TW200741203A (en) Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
EA201500080A1 (en) METHOD IN VITRO DIAGNOSIS AND MONITORING OF CANCER
WO2011146945A3 (en) Alk and ros kinase in cancer
MX339340B (en) Methods for predicting and improving the survival of gastric cancer patients.
MX2019002929A (en) Rna biomarkers for hereditary angioedema.
WO2015077382A3 (en) Combined cytology and molecular testing for early detection of esophageal adenocarcinoma
WO2012103337A3 (en) Assays and methods to sequence microbes directly from immune complexes
SG10201806729VA (en) Novel assay to detect human periostin
PH12014501445B1 (en) Detection of human umbilical cord tissue-derived cells
AU2013231230A8 (en) Method for selecting or identifying a subject for V1B antagonist therapy
MX2015007494A (en) Method for the diagnosis of metachromatic leukodystrophy.
MY192159A (en) Method for detecting neutralizing antibodies against recombinant human insulin in human serum
MX2013004069A (en) Immunoreactive antigens of mycoplasma heamofelis and diagnostic immunoassay.